Investigating chemokines and chemokine receptors in patients with multiple sclerosis: Opportunities and challenges

Archives of Neurology

Volumn 58, Issue 12, 2001, Pages 1975-1980

  Trebst, Corinna ^a   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

AUTOIMMUNE DISEASE; AUTOPSY; BODY FLUID; BRAIN BIOPSY; DEMYELINATING DISEASE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; HUMAN; LEUKOCYTE MIGRATION; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0035203885     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.12.1975     Document Type: Review

References (45)

1. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
2. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology; XXII: nomenclature for chemokine receptors. Pharmacol Rev. 2000;52:145-176.
3. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-445.
4. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033-1036.
5. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996; 272:60-66.
6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
7. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol. 1994;6:865-873.
8. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol. 1997; 58:52-59.
9. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 2000;102:98-106.
10. Barcellos LF, Schito AM, Rimmler JB, et al, for the Multiple Sclerosis Genetics Group. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics. 2000;51:281-288.
11. Fiten P, Vandenbroeck K, Dubois B, et al. Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J Neuroimmunol. 1999;95:195-201.
12. Teuscher C, Butterfield RJ, Ma RZ, et al. Sequence polymorphisms in the chemokines Scyal (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J Immunol. 1999;163:2262-2266.
13. Nguyen GT, Carrington M, Beeler JA, et al. Phenotypic expressions of CCR5-Δ32/Δ32 homozygosity. J Acquir Immune Defic Syndr. 1999;22:75-82.
14. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97: 1925-1928.
15. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807-815.
16. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(t) T cells are increased in multiple sclerosis and their ligands MIP-1a and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999;96: 6873-6878.
17. Calabresi PA, Martin R, Jacobson S. Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. J Neurovirol. 1999;5:102-108.
18. + interferon-γ-and tumor necrosis factor α-secreting T lymphocytes in multiple sclerosis. Ann Neurol. 2000;47:269-273.
19. Zang YC, Samanta AK, Halder JB, et al. Aberrant T cell migration toward RANTES and MIP-1α in patients with multiple sclerosis: overexpression of chemokine receptor CCR5. Brain. 2000;123(pt 9):1874-1882.
20. Misu T, Onodera H, Fujihara K, et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol. 2001; 114:207-212.
21. + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol. In press.
22. Simpson J, Rezaie P, Newcombe J, et al. Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol. 2000;108:192-200.
23. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2000;26:133-142.
24. Zang YC, Halder JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β. J Neuroimmunol. 2001; 112:174-180.
25. Wandinger KP, Stürzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001;50:349-357.
26. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med. 2000; 192:899-906.
27. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med. 2000;192:1075-1080.
28. Rottman JB, Slavin AJ, Silva R, et al. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol. 2000; 30:2372-2377.
29. + cells in the immunopathogenesis of experimental allergic encephalomyelitis (EAE) [abstract]. FASEB J. 1999;13:666.
30. Prat E, Baron PL, Meda L, et al. Interferon-γ-inducible protein-10 is increased in the cerebrospinal fluid of patients with multiple sclerosis [abstract). Mult Scler. 2000;5:83.
31. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol. 2001;115:192-198.
32. Mahad DJ, Woodroofe MN, Howell SJ. Chemokine expression in cerebrospinal fluid of multiple sclerosis [abstract]. Ann Neurol. 2000;48:452.
33. Sindern E, Niederkinkhaus Y, Henschel M, et al. Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2001;104:88-91.
34. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol. 1998;84:238-249.
35. Woodroofe N, Cross AK, Harkness K, Simpson JE. The role of chemokines in the pathogenesis of multiple sclerosis. Adv Exp Med Biol. 1999;468:135-150.
36. Van Der Voorn P, Tekstra J, Beelen RH, et al. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol. 1999;154: 45-51.
37. McManus C, Berman JW, Brett FM, et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol. 1998;86:20-29.
38. Boven LA, Montagne L, Nollet HS, de Groot CJ. Macrophage inflammatory protein-1α (MIP-1α), MIP-1β, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin Exp Immunol. 2000;122:257-263.
39. Hvas J, McLean C, Justesen J, et al. Perivascular T cells express the proinflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand J Immunol. 1997;46:195-203.
40. Baranzini SE, Elfstrom C, Chang SY, et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol. 2000;165:6576-6582.
41. Huang D, Han Y, Rani MR, et al. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev. 2000;177:52-67.
42. Kivisäkk P, Teleshova N, Ozenci V, et al. No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. J Neuroimmunol. 1998;91:108-112.
43. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47: 707-717.
44. Wu XM, Osoegawa M, Yamasaki K, et al. Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) and hyperlgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci. 2000;177:24-31.
45. Ransohoff RM, Bacon KB. Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs. 2000;9:1079-1097.